Xeris Biopharma Sets New Revenue Records and Projects More Than 30% Growth for 2026
Market Chameleon (Mon, 2-Mar 2:57 AM ET)
Business Wire (Mon, 2-Mar 7:00 AM ET)
Xeris Biopharma Subsidiaries File Recorlev Patent Infringement Lawsuit
Business Wire (Thu, 26-Feb 5:55 PM ET)
Business Wire (Tue, 17-Feb 7:30 AM ET)
Xeris Projects Record 2025 Revenues, Driven by Strong Growth in Recorlev, Gvoke, and Keveyis
Market Chameleon (Thu, 8-Jan 3:41 AM ET)
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
Business Wire (Thu, 8-Jan 7:00 AM ET)
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire (Fri, 2-Jan 4:15 PM ET)
Xeris Biopharma Achieves Record Q3 Results as Recorlev Revenue Surges 109%—Guidance Raised for 2025
Market Chameleon (Thu, 6-Nov 2:59 AM ET)
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
Xeris Biopharma Holdings trades on the NASDAQ stock market under the symbol XERS.
As of March 17, 2026, XERS stock price climbed to $5.59 with 361,910 million shares trading.
XERS has a beta of 1.43, meaning it tends to be more sensitive to market movements. XERS has a correlation of 0.15 to the broad based SPY ETF.
XERS has a market cap of $927.52 million. This is considered a Small Cap stock.
Last quarter Xeris Biopharma Holdings reported $86 million in Revenue and $.06 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, XERS traded as high as $10.08 and as low as $1.25.
The top ETF exchange traded funds that XERS belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.
XERS has underperformed the market in the last year with a price return of +16.0% while the SPY ETF gained +20.6%. XERS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.3% and -7.1%, respectively, while the SPY returned -0.8% and -2.1%, respectively.
XERS support price is $5.33 and resistance is $5.65 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XERS shares will trade within this expected range on the day.
